[ad_1]
(Pexel)
SAO PAULO – This Wednesday (18), the American pharmaceutical company Pfizer and the German biotechnology company BioNTech announced the conclusion of phase three of clinical trials for their vaccine against covid-19.
Completion of testing shows greater effectiveness than previously announced by Pfizer’s CEO. According to the most recent results, the vaccine was 95% effective in preventing the disease and had no serious side effects.
It should be remembered that, although clinical tests have been carried out, the results have not yet been published in any scientific journal so that other scientists can verify them.
To reach the conclusion, Pfizer analyzed the data after 170 volunteers contracted Covid-19. There were more than 40,000 volunteers between the United States, Argentina, Brazil, Germany, Turkey and South Africa, half received the real vaccine and the other half, an inactive substance with no effect (placebo).
According to the pharmaceutical company, the effectiveness of immunity begins 28 days after the application of the first dose. Two doses are required per person. Of the 170 infected, only eight received the experimental vaccine and 162 received the placebo. Pfizer concluded that the effectiveness of its vaccine is 95%.
The drugmaker noted that all the safety ratings for emergency use authorization required by the US health regulatory agency, the Food and Drug Administration (FDA), have been achieved.
The FDA had previously announced that any vaccine must demonstrate 50% effectiveness prior to launch. Additionally, companies that test immunizers must screen half of their participants for side effects for at least two months, the time period when problems usually appear. Pfizer expects to hit the mark later this month.
According to the pharmacist, so far there have been no serious cases of Covid-19 among the participants. With that, Pfizer said it intends to request emergency use of its vaccine “in a few days,” without giving a specific date.
The company also reported that it plans to produce 50 million doses of the vaccine globally in 2020 and 1.3 billion doses by the end of 2021.
The Unknown Side of Options – Free InfoMoney Training Teaches You How to Turn Assets Into a Recurring Source of Income – Look!
[ad_2]
